An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma.
Immune-based treatments represent a promising new class of therapy designed to boost the immune system to specifically eradicate malignant cells. Immunotherapy may generate specific anti-tumor immune responses, and dendritic cells (DC), professional antigen-presenting cells, are widely used in exper...
Main Authors: | Sara Nava, Marta Dossena, Simona Pogliani, Serena Pellegatta, Carlo Antozzi, Fulvio Baggi, Cinzia Gellera, Bianca Pollo, Eugenio A Parati, Gaetano Finocchiaro, Simona Frigerio |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23284979/pdf/?tool=EBI |
Similar Items
-
PGE<sub>2</sub> Is Crucial for the Generation of FAST Whole- Tumor-Antigens Loaded Dendritic Cells Suitable for Immunotherapy in Glioblastoma
by: Sara Nava, et al.
Published: (2020-03-01) -
Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide
by: Serena Pellegatta, et al.
Published: (2018-04-01) -
Advanced MRI Assessment during Dendritic Cell Immunotherapy Added to Standard Treatment Against Glioblastoma
by: Valeria Cuccarini, et al.
Published: (2019-11-01) -
Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma
by: Broggi Giovanni, et al.
Published: (2004-10-01) -
Introduction to dendritic cell vaccines immunotherapy for glioblastoma multiforme : A novel approach
by: Terawan Agus Putranto, et al.
Published: (2019-04-01)